Abstract: Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating the recombinant adeno-associated viral capsid proteins and a library from which the capsids are selected are also provided.
Type:
Grant
Filed:
March 30, 2007
Date of Patent:
September 15, 2009
Assignee:
Board of Trustees of the Leland Stamford Junior University
Abstract: The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. The invention also relates to the development and use of IFN-deficient systems for selection of such attenuated viruses. In particular, the invention relates to attenuated influenza viruses having modifications to the NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. The mutant viruses replicate in vivo but demonstrate reduced pathogenicity, and therefore are well suited for live virus vaccines, and pharmaceutical formulations.
Type:
Grant
Filed:
November 14, 2003
Date of Patent:
September 15, 2009
Assignee:
Mount Sinai School of Medicine of New York University
Inventors:
Peter Palese, Adolfo Garcia-Sastre, Thomas Muster
Abstract: Therapeutic methods and microorganisms therefore are provided. The microorganisms are designed to accumulate in immunoprivileged tissues and cells, such as in tumors and other proliferating tissue and in inflamed tissues, compared to other tissues, cells and organs, so that they exhibit relatively low toxicity to host organisms. The microorganisms also are designed or modified to result in leaky cell membranes of cells in which they accumulate, resulting in production of antibodies reactive against proteins and other cellular products and also permitting exploitation of proliferating tissues, particularly tumors, to produce selected proteins and other products. Methods for making tumor specific antibodies and also methods of making gene products encoded by the microorganism as well as antibodies reactive therewith are provided.
Type:
Grant
Filed:
June 18, 2004
Date of Patent:
September 15, 2009
Assignee:
Genelux Corporation
Inventors:
Aladar A. Szalay, Tatyana Timiryasova, Yong A. Yu, Qian Zhang
Abstract: The present invention provides a synthetic nucleic acid sequence comprising 10-30 nucleotides of the N gene region and/or the 3? non-coding region of the SARS-associated coronavirus genome, and a synthetic nucleic acid sequence comprising 10-30 nucleotides of a nucleic acid sequence that is complementary to at least one of those regions. Also provided are compositions comprising the sequences, and uses of the sequences in diagnostic kits. The present invention further provides a primer set for determining the presence or absence of SARS-associated coronavirus in a biological sample, wherein the primer set comprises at least one of the synthetic nucleic acid sequences. Also provided are a composition comprising the primer set, and use of the primer set in a diagnostic kit. Finally, the present invention provides kits and methods for determining the presence or absence of SARS-associated coronavirus in a biological sample.
Type:
Grant
Filed:
January 23, 2004
Date of Patent:
September 1, 2009
Assignee:
The Trustees of Columbia University In the City of New York
Inventors:
Thomas Briese, W. Ian Lipkin, Gustavo Palacios, Omar Jabado
Abstract: The invention provides a novel method of vaccination of an animal of the felidae family against feline leukemia. The FeLV recombinant vaccine based on viral vector with the aid of a liquid jet needle-free injector can result in distribution of the vaccine essentially in the dermis and the hypodermis of the animal.
Type:
Grant
Filed:
June 6, 2005
Date of Patent:
September 1, 2009
Assignee:
Merial Limited
Inventors:
Tesfai Tseggai, Maria Camila Pardo, Alton Timothy Leard
Abstract: This invention relates to an SRSV detection kit comprising all antibodies against SRSV-related virus constituting peptides selected from the following peptide groups (a) to (k), respectively: (a) a peptide having an amino acid sequence represented by SEQ ID NO: 1, and the like, (b) a peptide having an amino acid sequence represented by SEQ ID NO: 2, and the like, (c) a peptide having an amino acid sequence represented by SEQ ID NO: 3, and the like, (d) a peptide having an amino acid sequence represented by SEQ ID NO: 4, and the like, (e) a peptide having an amino acid sequence represented by SEQ ID NO: 5, and the like, (f) a peptide having an amino acid sequence represented by SEQ ID NO: 6, and the like, (g) a peptide having an amino acid sequence represented by SEQ ID NO: 7, and the like, (h) a peptide having an amino acid sequence represented by SEQ ID NO: 8, and the like, (i) a peptide having an amino acid sequence represented by SEQ ID NO: 9, and the like, (j) a peptide having an amino acid sequence repre
Type:
Grant
Filed:
April 13, 2006
Date of Patent:
August 18, 2009
Assignees:
Japan as Represented by Director-General National Institute of Infectious Diseases, Denka Seiken Co., Ltd.
Abstract: The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof.
Type:
Grant
Filed:
January 11, 2005
Date of Patent:
August 11, 2009
Assignee:
Wisconsin Alumni Research Foundation
Inventors:
Christopher W. Olsen, Gabriele A. Landolt, Alexander I. Karasin
Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare human papillomavirus (HPV) epitopes, and to develop epitope-based vaccines directed towards HPV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HPV infection.
Type:
Grant
Filed:
December 11, 2000
Date of Patent:
August 11, 2009
Assignee:
Pharmexa Inc.
Inventors:
Alessandro Sette, John Sidney, Scott Southwood, Robert Chesnut, Esteban Celis, Howard M. Grey
Abstract: A method of detecting, characterizing and treating viral infection is provided. In particular, a strategy of molecular mimicry is provided for characterizing viral behavior and/or a predisposition for a given viral outcome in vivo. Novel compositions are also provided for detecting, characterizing and treating viral infections.
Abstract: The present invention relates to compositions comprising humanized antibodies or fragments thereof that immunospecifically bind to one or more antigens of a flavivirus, particularly of West Nile Virus (WNV) and methods for preventing, treating or ameliorating symptoms associated with a flavivirus, particularly of West Nile Virus (WNV) infection utilizing said compositions. In particular, the present invention relates to methods for preventing, treating or ameliorating symptoms associated with WNV infection, said methods comprising administering to a human subject an effective amount of one or more humanized antibodies or fragments thereof that immunospecifically bind to a WNV antigen. The present invention also relates to detectable or diagnostic compositions comprising humanized antibodies or fragments thereof that immunospecifically bind to a WNV antigen and methods for detecting or diagnosing WNV infection utilizing said compositions.
Abstract: Attenuated pestiviruses, in particular attenuated BVDV, wherein at least one mutation is in the coding sequence for glycoprotein Erns and at least another mutation in the coding sequence for Npro which preferably leads to combined inactivation of the RNase activity residing in glycoprotein Erns in addition to the inactivation of the (hypothesized) immunomodulating activity residing in Npro. Methods for attenuating pestiviruses such as BVDV, nucleic acids encoding the pestiviruses, in particular BVDV, compositions and vaccines comprising the attenuated pestiviruses, in particular BVDV, of the invention.
Type:
Grant
Filed:
May 19, 2005
Date of Patent:
August 11, 2009
Assignee:
Boehringer Ingelheim Vetmedica GmbH
Inventors:
Gregor Meyers, Andreas Ege, Christiane Fetzer, Martina von Freyburg
Abstract: The invention provides compositions and methods for the detection and quantification of PRRSV antibodies and antibody fragments using polypeptides.
Abstract: The invention relates to an anti-inflammatory oligopeptide which can be obtained from the microorganism Entamoeba histolytica or synthesized by known methods. The oligopeptides are useful in treating inflammatory diseases when formulated in pharmaceutical compositions for administration to patients.
Abstract: The invention provides chimeric flavivirus vectors including foreign peptides inserted into the envelope proteins of the vectors and methods of using these vectors.
Type:
Grant
Filed:
May 31, 2002
Date of Patent:
August 4, 2009
Assignee:
Acambis Inc.
Inventors:
Harold Kleanthous, Charles Miller, Larisa Oros
Abstract: Codon-optimized nucleic acids encoding influenza polypeptides and uses of the nucleic acids and polypeptides for inducing immune responses are provided herein.
Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
Type:
Grant
Filed:
June 16, 2004
Date of Patent:
July 28, 2009
Assignee:
MedImmune, LLC
Inventors:
Chin-Fen Yang, George Kemble, Chongguang Liu
Abstract: The present invention relates to methods for treating or preventing diseases or disorders in a pregnant cow and calf nursing a pregnant cow caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus (PIV3), Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardjo-prajitno, Leptospira icterohaemorrhagia, Leptospira hardjo-bovis and Leptospira pomona by administering to the animal an effective amount of a safe modified live viral combination vaccine further combined with a multivalent bacterin vaccine.
Type:
Grant
Filed:
April 21, 2003
Date of Patent:
July 21, 2009
Assignee:
Pfizer Inc,
Inventors:
Michael A. Ellsworth, Martin D. Ficken, Brian J. Fergen, Cassius M. Tucker
Abstract: A single isolated antibody or antibody fragment thereof binds to multiple variant sequences within an epitope of HIV-1 Tat protein displayed in multiple strains and subtypes of HIV-1. This “pan-epitope” antibody is useful in therapeutic and prophylactic compositions and treatments of HIV-1 infection, regardless of strain. This pan-epitope antibody is useful in assays for the detection of levels of HIV-1 based on a measurement of the amount of Tat protein in a biological sample.
Type:
Grant
Filed:
February 13, 2006
Date of Patent:
July 21, 2009
Assignee:
Thymon, LLC
Inventors:
Roland Carlsson, Elisabeth Sonesson, Yvonne Stenberg, Leif Strandberg, Gideon Goldstein
Abstract: The invention is directed to a poxvirus vaccine comprising a soluble truncated poxvirus envelope protein. The invention is also directed to a vaccine comprising a nucleic acid encoding such proteins. Also included is an antibody which specifically binds to the proteins and nucleic acid encoding the same, as well as methods of preventing and treating a poxvirus infection using the afore-mentioned vaccine, antibody, protein, and nucleic acid encoding them.
Type:
Grant
Filed:
December 13, 2004
Date of Patent:
July 14, 2009
Assignee:
The Trustees of the University of Pennsylvania
Inventors:
Gary H. Cohen, Roselyn J. Eisenberg, John Charles Whitbeck, Lydia Aldaz-Carroll, Bernard Moss, Shlomo Lustig, Christiana Fogg
Abstract: The present invention relates to a highly processive reverse transcriptase having DNA polymerase activity and substantially reduced protease activity. More specifically, the invention relates to an isolated reverse transcriptase from foamy virus comprising a substantially inactivated protease. The invention also relates to vectors containing the gene and hosts transformed with the vector of the invention. Further, the invention relates to a method for producing reverse transcriptase having DNA polymerase activity and substantially reduced protease activity by expressing the reverse transcriptase genes of the present invention in a recombinant host. Methods are also provided for producing cDNA from polynucleotides using the highly processive reverse transcriptase of the invention. Kits for the preparation of cDNA from RNA comprising the highly processive reverse transcriptase of the invention are also provided.
Type:
Grant
Filed:
May 22, 2002
Date of Patent:
July 14, 2009
Assignee:
Fred Hutchinson Cancer Research Center
Inventors:
Stephen Hughes, Paul Boyer, Maxine Linial, Carolyn Stenbak, Patrick Clark